|
|
The first oral chemotherapy drug for colon cancer was approved by FDA in 2001.
Fatal fungal infections may be able to resist newer antifungal drugs. Globally, fungal infections are often fatal due to the lack of access to multiple antifungals, which may be required to be utilized in combination. Single antifungals may not be enough to stop a fungal infection from causing the death of a patient.
In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.
Multiple experimental evidences have confirmed that at the molecular level, cancer is caused by lesions in cellular DNA.
Women are 50% to 75% more likely than men to experience an adverse drug reaction.